• 2025
• 2024
• 2023
• 2022
• 2021
• 2020
• 2019
• 2018
• 2017
• 2016
• 2015
• 2014
• 2013
• 2012
• 2011
• 2010
• 2009
• 2008
• 2007
• 2006
• 2005
• 2004
• 2003
• 2002
• 2001
• 2000
• 1999
• 1998
• 1997
• 1996
• 1995
• 1993

2025

• Patrick Opitz1, Isabel Waltering1, and Georg Hempel1, * 1. Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, University of Muenster, und Muenster, Germany. 2025. „Development and Validation of a Quantification Method for Direct Oral Anticoagulants from Capillary Blood using volumetric absorptive microsampling and online SPE-LC-MS.“ Journal of Chromatography B, Nr. 1251 124423. doi: https://doi.org/10.1016/j.jchromb.2024.124423.

2024

• Zimbelmann, F, Flaute, S, Deipenbrock, M, Ahlke, E, Hempel, G, und Baumann-Köhler, M. 2024. „Anwendung stark wirksamer retardierter Opioide in der Pädiatrie : Fallstricke und Lösungen für Morphin und Hydromorphon.“ Schmerz, Nr. 204 doi: 10.1007/s00482-023-00775-w.
• Bauch, T, und Hempel, G. 2024. „Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.“ British Journal of Haematology, Nr. 204 (6): 2324–2331. doi: 10.1111/bjh.19410.
• Opitz, P, Fobker, M, Fabian, J, und Hempel, G. 2024. „Development and validation of a bioanalytical method for the quantification of methotrexate from serum and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.“ Journal of Chromatographic Science, Nr. 1715 464610. doi: 10.1016/j.chroma.2023.464610.
• Ramadan, O.[1], Opitz, P.[2 3], und Hempel, G.[4]. 2024. „Development and Validation of a High-Performance Liquid Chromatography With Ultraviolet Detection Method to Facilitate Therapeutic Monitoring of Teicoplanin Using Dried Blood Spots.“ Therapeutic Drug Monitoring, Nr. 00: 1–7. doi: 10.1097/FTD.0000000000001202.

2023

• Schatz, LM, Brinkmann, A, Röhr, A, Frey, O, Greppmair, S, Weinelt, F, Zoller, M, Scharf, C, Hempel, G, und Liebchen, U. 2023. „Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.“ Antimicrobial Agents and Chemotherapy, Nr. 1 doi: 10.1128/aac.00104-23.
• Rosser, SPA, McLachlan, AJ, Hempel, G, Chung, J, Shaw, PJ, Keogh, SJ, und Nath, CE. 2023. „Validation of a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of N,N-dimethylacetamide and N-monomethylacetamide in pediatric plasma.“ Journal of Separation Science, Nr. 46 (10) doi: 10.1002/jssc.202201003.
• Ramadan O, Schatz LM, van den Heuvel I, Masjosthusmann K, Groll AH, Hempel G. 2023. „Developing a Method for Quantifying Meropenem in Children-Volumetric Adsorptive Microsampling Versus Plasma Sampling.“ Therapeutic Drug Monitoring, Nr. 45 (5): 623–630.
• Gastine, SE; Rauwolf, KK; Pieper, S; Hempel, G; Lehrnbecher, T; Tragiannidis, A; Groll, AH. 2023. „Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age.“ Mycoses, Nr. 66 (11): 969–976.
• Maierhöfer, S, Waltering, I, Würthwein, G, Jacobs, M, und Hempel, G. 2023. „Ein klinisches Entscheidungsunterstützungssystem für Medikationsanalysen in öffentlichen Apotheken: patientenberichtete Endpunkte der OPtiMed-Studie.“ präsentiert auf der Annual Meeting of the German Society of Clinical Pharmacy – DGKPha, Münster
• Opitz, P, Zimmermann, S, Stapf, M, Klima, F, Müller, L, Fuxius, S, Illerhaus, G, Scherf-Clavel, O, Kloft, C, und Hempel, G. 2023. „Erweiterung einer bioanalytischen Methode für das therapeutische Drug Monitoring von Axitinib in Plasma und Kapillarblut zu einer generischen Methode für orale Onkologika.“ präsentiert auf der Jahrestagung der Deutschen Gesellschaft für Klinische Pharmazie DGKPha, Münster

2022

• Khalil, A; Würthwein, G; Golitsch, J; Hempel, G; Fobker, M; Gerss, J; Möricke, A; Zimmermann, M; Smisek, P; Zucchetti, M; Nath, C; Attarbaschi, A; Von Stackelberg, A; Gökbuget, N; Rizzari, C; Conter, V; Schrappe, M; Boos, J; Lanvers-Kaminsky, C. 2022. „Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.“ Haematologica, Nr. 107 (1): 49–57. doi: 10.3324/haematol.2020.258525.
• Opitz, Patrick, Zimmermann, Sebastian, Mc Laughlin, M.Anna, Müller, Lothar, Fuxius, Stefan, Illerhaus, Gerald, Scherf-Clavel, Oliver, Kloft, Charlotte, und Hempel, Georg. 2022. „Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.“ Journal of Pharmaceutical and Biomedical Analysis, Nr. 221 115033. doi: 10.1016/j.jpba.2022.115033.
• Lea Marie Schatz, Georg Hempel, und Ferdinand Anton Weinelt, Uwe Liebchen. 2022. „Systematic evaluation of meropenem pharmacokinetic models for Bayesian forecasting in critically ill patients undergoing continuous renal replacement therapy.“ präsentiert auf der Quantitative Systems Pharmacology Conference 2022, Leiden
• Schatz, Lea Marie, Wicha, Sebastian G., Hempel, Georg, de Hoog, Matthijs, Allegaert, Karel, Knibbe, CatherijneA.J, und Völler, Swantje. 2022. „Model-informed precision dosing for vancomycin in children between 28 days and 18 years: Does the use of a multi-model approach improve the predictive performance?“ präsentiert auf der Population Approach Group Europe 2022 (PAGE), Ljubljana
• Hirn-Derksen, B., Ryu, C., Hyunki, C., Kim, J.Y., und Hempel, G. 2022. „Development of a pharmacokinetic model to predict disposition of Dutasteride in zebrafish embryos.“ präsentiert auf der Population Approach Group Europe 2022 (PAGE), Ljubljana
• Shahhossini, Morwarid, Lehmann, Florian, Schmidt, Christina, Arnemann, Philip-Helge, Kaiser, Luca Elisa, Ertmer, Christian, Hempel, Georg, und Hessler, Michael. 2022. „Plasmakonzentration von Vancomycin nach Hämadsorption mit Cytosorb®.“ präsentiert auf der Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI), Hamburg
• Morwarid, Shahhossini., Hessler, Michael, und Hempel, Georg. 2022. „Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock.“ präsentiert auf der Population Approach Group Europe 2022 (PAGE), Ljubljana
• Mohamed, Fakry F., Anhlan, Darisuren, Schöfbänker, Michael, Schreiber, André, Classen, Nica, Hensel, Andreas, Hempel, Georg, Scholz, Wolfgang, Kühn, Joachim, und Hrincius, Eike R. Stephan Ludwig. 2022. „Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2.“ Pharmaceuticals, Nr. 15 (5) doi: 10.3390/ph15050530.
• Maierhöfer, S; Waltering, I; Jacobs, M; Würthwein, G; Appelrath, M; Koling, S; Hempel, G. 2022. „Decision support software-guided medication reviews in elderly patients with polypharmacy: a prospective analysis of routine data from community pharmacies (OPtiMed study protocol).“ Journal of Pharmaceutical Policy and Practice, Nr. 15 (1) doi: 10.1186/s40545-022-00495-z.
• Maierhöfer, S, Waltering, I, Jacobs, M, Appelrath, M, und Hempel, G. 2022. „Developing a questionnaire comprising clinically useful patient-reported outcome measures in software-assisted medication reviews.“ Beitrag präsentiert auf der Jahrestagung der deutschen Gesellschaft für klinische Pharmazie, Heidelberg
• Khalil, A, Würthwein, G, Golitsch, J, Hempel, G, Fobker, M, Gerss, J, Möricke, A, Zimmermann, M, Smisek, P, Zucchetti, M, Nath, C, Attarbaschi, A, Von Stackelberg, A, Gökbuget, N, Rizzari, C, Conter, V, Schrappe, M, Boos, J, und Lanvers-Kaminsky, C. 2022. „Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.“ Haematologica, Nr. 107 (1) doi: 10.3324/haematol.2020.258525.
• Bognàr, T, Bartelink, IH, Egberts, T, Rademaker, C, Versluys, B, Slatter, MA, Kletzel, M, Nath, CE, Cuvelier, GDE, Savic, RM, Dvorak, C, Long-Boyle, JR, Cowan, MJ, Bittencourt, H, Bredius, M, Güngör, T, Shaw, PJ, Ansari, M, Hassan, M, Krajinovic, M, Hempel, G, Marktel, S, Chiesa, R, Théoret, Y, Lund, T, Orchard, PJ, Wynn, RRF, Boelens, J, und Lalmohamed, A. 2022. „Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation.“ Cellular Therapy and Transplantation, Nr. 22 doi: 10.1016/j.jtct.2022.01.013.

2021

• Würthwein, G, Lanvers-Kaminsky, C, Siebel, C, Gerß, J, Möricke, A, Zimmermann, M, Stary, J, Smisek, P, Schrappe, M, Rizzari, C, Zucchetti, M, Hempel, G, Wicha, SG, und Boos, J. 2021. „Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.“ European Journal of Drug Metabolism and Pharmacokinetics, Nr. 46 (2): 289–300. doi: 10.1007/s13318-021-00670-8.
• Shahhossini, Morwarid, Hessler, Michael, und Hempel, Georg. 2021. „Untersuchung der Adsorption von Ciprofloxacin in vivo nach Hämoadsorption mit CytoSorb®.“ präsentiert auf der Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), digital
• Schatz, L.M., Ramadan, O., Groll, A., Masjosthusmann, K., van den Heuvel, A., und Hempel, G. 2021. „Therapeutisches Drug Monitoring und Dosisoptimierung von Meropenem, basierend auf kleinen Probenvolumina bei kritisch kranken Kindern.“ präsentiert auf der Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), online
• Maierhöfer, S, Waltering, I, Gillessen, A, Würthwein, G, und Hempel, G. 2021. „Effekte Software-gestützter Medikationsanalysen auf die Angemessenheit der Medikation und auf patientenberichtete Endpunkte bei geriatrischen Patienten mit Polypharmazie: eine prospektive Analyse von Routinedaten aus öffentlichen Apotheken (OptiMed- Studienprotokoll).“ präsentiert auf der Annual Meeting of the German Society of Clinical Pharmacy - DGKPha, München
• Maierhöfer, S, Waltering, I, Riebel, S, und Hempel, G. 2021. „Effectiveness of clinical decision support systems for managing drug therapy: a systematic review within the scope of a clinical evaluation of a medical device.“ präsentiert auf der 12th PCNE working conference, Basel doi: 10.1007/s11096-21-01269-4.
• McLaughlin1, A.M., Schmulenson2, E, Teplytska2, O, Zimmermann3, S, Opitz, P, Groenland4, S.L., Huitema45, A.D.R., Steeghs4, N., Müller6, L., Fuxius7, S., Illerhaus8, G., Joerger9, M., Mayer10, F., Fuhr11, U., Holdenrieder12, S., Hempel, G., Scherf-Clavel3, O., Jaehde2, U., und Kloft1, C. 2021. „Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.“ Cancers, Nr. 13 (24): 1–15. doi: 10.3390/cancers13246281.
• Spiegler, V, Greiffer, L, Jacobtorweihen, J, Asase, A, Lanvers-Kaminsky, C, Hempel, G, Agyare, C, und Hensel, A. 2021. „In vitro screening of plant extracts traditionally used as cancer remedies in Ghana - 15-Hydroxyangustilobine A as the active principle in Alstonia boonei leaves.“ Journal of Ethnopharmacology, Nr. 2021 doi: 10.1016/j.jep.2020.113359.
• Rimmler, Ch, Lanckohr, Ch, Mittrup, M, Welp, H, Würthwein, G, Horn, D, Fobker, M, Ellger, B, und Hempel, G. 2021. „Population pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis during and after cardiopulmonary bypass.“ British Journal of Clinical Pharmacology, Nr. 87 (3): 1486–1498.
• Mc, Laughlin AM, Schmulenson, E, Teplytska, O, Zimmermann, S, Opitz, P, Groenland, SL, Huitema, ADR, Steeghs, N, Müller, L, Fuxius, S, Illerhaus, G, Joerger, M, Mayer, F, Fuhr, U, Holdenrieder, S, Hempel, G, Scherf-Clavel, O, Jaehde, U, und Kloft, C. 2021. „Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. For The On-Target Study Consortium.“ Cancers, Nr. 13 (24) doi: 10.3390/cancers1324628.
• Blume, H, Mehta, M, Beuerle, G, Dorantes, A, Hempel, G, Jiang, W, Kovar, A, Lee, J, Potthast, H, Schug, B, Seidlitz, A, Tampal, N, Tsang, Y, Walstab, J, und Welink, J. 2021. „The Global Bioequivalence Harmonisation Initiative (GBHI): Report of EUFEPS/AAPS fourth conference.“ European Journal of Pharmaceutical Sciences, Nr. 2021 doi: 10.1016/j.ejps.2021.105987.
• Barnett, S, Hellmann, F, Parke, E, Makin, G, Tweddle, DA, Osborne, C, Hempel, G, und Veal, GJ. 2021. „Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients.“ European Journal of Cancer (1965), Nr. 2021 doi: 10.1016/j.ejca.2021.09.014.
• Jalusic, KO, Hempel, G, Arnemann, PH, Spiekermann, C, Kampmeier, TG, Ertmer, C, Gastine, S, und Hessler, M. 2021. „Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis.“ British Journal of Clinical Pharmacology, Nr. 87 (6)
• Zubiaur, P, Kneller, LA, Ochoa, D, Mejía, G, Saiz-Rodríguez, M, Borobia, AM, Koller, D, García, IG, Navares-Gómez, M, Hempel, G, und Abad-Santos, F. 2021. „Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.“ Clinical Pharmacokinetics, Nr. 60 (2)
• Gastine, S, Hope, W, Hempel, G, Petraitiene, R, Petraitis, V, Mickiene, D, Bacher, J, Walsh, TJ, und Groll, AH. 2021. „Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.“ Antimicrobial Agents and Chemotherapy, Nr. 65 (2) doi: 10.1128/AAC.01574-20.
• Kneller, LA, Zubiaur, P, Koller, D, Abad-Santos, F, und Hempel, G. 2021. „Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.“ Clinical Pharmacokinetics, Nr. 2021 (Jun 14) doi: 10.1007/s40262-021-01041-x.
• Waltering, Isabell, Schwalbe, Olaf, und Hempel, Georg. 2021. „Identification of factors for a successful implementation of medication reviews in community pharmacies: Using Positive Deviance in pharmaceutical care.“ International Journal of Clinical Pharmacy, Nr. 44 (1) doi: 10.1007/s11096-021-01315-1.
• Opitz, Patrick, Stern, Mike, und Hempel, Georg. 2021. „Entwicklung und Validierung einer quantitativen Methode zur Bestimmung von direkten oralen Antikoagulantien aus Kapillarblut unter Verwendung von VAMSTM und online SPE-LC-MS.“ präsentiert auf der Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), digital

2020

• Siebel, C, Lanvers-Kaminsky, C, Würthwein, G, Hempel, G, und Boos, J. 2020. „Bioanalysis of doxorubicin aglycone metabolites in human plasma samples-implications for doxorubicin drug monitoring.“ Scientific Reports, Nr. 10 (1): 18562. doi: 10.1038/s41598-020-75662-w.
• Khalil, A, Würthwein, G, Golitsch, J, Hempel, G, Fobker, M, Gerss, J, Möricke, A, Zimmermann, M, Smisek, P, Zucchetti, M, Nath, C, Attarbaschi, A, Stackelberg, A, Gökbuget, N, Rizzari, C, Conter, V, Schrappe, M, Boos, J, und Lanvers-Kaminsky, C. 2020. „Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.“ Haematologica, Nr. Online ahead of print doi: 10.3324/haematol.2020.258525.
• Stern, M, Giebels, M, Fey, T, Lübking, M, Alferink, J, und Hempel, G. 2020. „Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs.“ Bioanalysis, Nr. 2020 Aug;12(16) doi: 10.4155/bio-2020-0136.
• Hempel, G. 2020. „Methods of Therapeutic Drug Monitoring including Pharmacogenetics 2nd Edition.“ In Handbook of Analytical Separations Series Volume 7:, herausgegeben von Elsevier B.V. Amsterdam.
• Hensel, A, Bauer, R, Heinrich, M, Spiegler, V, Kayser, O, Hempel, G, und Kraft, K. 2020. „Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.“ Planta Medica, Nr. 2020
• Hempel, G. 2020. „How physiologically-based pharmacokinetic models should be improved for drug development.“ Future Medicinal Chemistry, Nr. 12 (12) doi: 10.4155/fmc-2020-0074.
• Siebel, C, Würthwein, G, Lanvers-Kaminsky, C, André, N, Berthold, F, Castelli, I, Chastagner, P, Doz, F, English, M, Escherich, G, Frühwald, MC, Graf, N, Groll, AH, Ruggiero, A, Hempel, G, und Boos, J. 2020. „Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.“ BMC pharmacology & toxicology, Nr. 21 (1) doi: 10.1186/s40360-020-00417-2.
• Dallmann, A, Himstedt, A, Solodenko, J, Ince, I, Hempel, G, und Eissing.T. 2020. „Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery.“ Journal of Pharmacokinetics and Pharmacodynamics, Nr. 47 (4)
• Hellmann, F, Völler, S, Krischke, M, Jamieson, D, André, N, Bisogno, G, Boddy, A, und Hempel, G. 2020. „Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.“ European Journal of Drug Metabolism and Pharmacokinetics, Nr. 45 (3)
• Berning, P, Hennemann, C, Tulotta, C, Schaefer, C, Lechtape, B, Hotfilder, M, El, Gourari Y, Jürgens, H, Snaar-Jagalska, E, Hempel, G, Dirksen, U, und Potratz, J. 2020. „The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma.“ Cancers, Nr. 12 (4)
• Kneller, LA, und Hempel, G. 2020. „Physiologically based pharmacokinetic modelling of risperidone and 9-hydroxyrisperidone to determine cytochrome P450 2D6 phenotypes in schizophrenia patients.“ In Bd. 53 aus Pharmacopsychiatry 2020 Stuttgart · New York: Georg Thieme Verlag KG. doi: 10.1055/s-0040-1710122.
• Kneller, LA, Abad-Santos, F, und Hempel, G. 2020. „Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.“ Clinical Pharmacokinetics, Nr. 59 (1) doi: 10.1007/s40262-019-00793-x.
• Kneller, LA, und Hempel, G. 2020. „Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.“ Pharmaceutical Research, Nr. 37 (6) doi: 10.1007/s11095-020-02843-7.
• Zubiaur, P, Kneller, LA, Ochoa, D, Mejía, G, Saiz-Rodríguez, M, Borobia, AM, Koller, D, García, IG, Navares-Gómez, M, Hempel, G, und Abad-Santos, F. 2020. „Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.“ Clinical Pharmacokinetics, Nr. 60 (2) doi: 10.1007/s40262-020-00941-8.
• Waltering, I, Scheppe, S, Kurth, V, Hempel, G, und Jaehde, U. 2020. „Qualitätsindikatoren zur Bewertung von Medikationsanalysen in öffentlichen Apotheken. (Quality indicators for medication reviews in community pharmacies).“ Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, Nr. 153-154 doi: 10.1016/j.zefq.2020.03.007.
• Stern, M, Giebels, M, Fey, T, Lübking, M, Alferink, J, und Hempel, G. 2020. „Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs.“ Bioanalysis, Nr. 12 (16) doi: 10.4155/bio-2020-0136.
• Stern, M, und Hempel, G. 2020. „Clinical validation study to derive conversion factors from capillary blood to plasma concentration for mirtazapine, quetiapine and norquetiapine.“ Beitrag präsentiert auf der IATDMCT 2020, Canada
• Lücht, UR, Geiben, AK, Brune, S, Scholz, WU, und Hempel, G. 2020. „Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals.“ In Pharmacopsychiatry , Bd. 3 aus 53 Stuttgart · New York: Georg Thieme Verlag KG. doi: 10.1055/s-0040-1710124.
• Siebel, Ch, Lanvers-Kaminsky, C, Würthwein, G, Hempel, G, und Boos, J. 2020. „Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring.“ Scientific Reports, Nr. 1 Vol (10): 18562. doi: 10.1038/s41598-020-75662.
• Dellinger, JK, Pitzer, S, Schaffler-Schaden, D, Schreier, MM, Fährmann, LS, Hempel, G, Likar, R, Osterbrink, J, und Flamm, M. 2020. „Improving medication appropriateness in nursing homes via structured interprofessional medication-review supported by health information technology: a non-randomized controlled study.“ BMC Geriatrics, Nr. 20 (1): 506. doi: 10.1186/s12877-020-01895-z.

2019

• Lücht, UR, Weber, J, Scholz, WU, Brune, S, und Hempel, G. 2019. „Physiologically based pharmacokinetic modelling approach to assess drug-drug interactions (DDi) between psychopharmaceuticals - focus on mirtazapine and venlafaxine.“ Beitrag präsentiert auf der XXVIIIth Meeting of the Population Approach Group Europe - PAGE, Stockholm, Sweden
• Hempel, G. 2019. „Pharmacotherapy in Children and Adolescents: Oncology.“ In Handb Exp Pharmacol, herausgegeben von Springer. doi: 10.1007/164_2019_306.
• Lehrnbecher, T, Bochennek, K, Klingebiel, T, Gastine, S, Hempel, G, und Groll, AH. 2019. „Extended Dosing Regimens for Fungal Prophylaxis.“ Clinical Microbiology Reviews, Nr. 2019 (32(3))
• Gastine, S, Lanckohr, C, Blessou, M, Horn, D, Fobker, M, Bause, D, Hempel, G, und Ellger, B. 2019. „Pharmacokinetics of Micafungin in Critically Ill Patients.“ Scientific Reports, Nr. 9(1) doi: 10.1038/s41598-019-53093-6.
• Jackson, RK, Liebich, M, Berry, P, Errington, J, Liu, J, Parker, C, Moppett, J, Samarasinghe, S, Hough, R, Rowntree, C, Goulden, NJ, Vora, A, Kearns, PR, Saha, V, Hempel, G, Irving, JAE, und Veal, GJ. 2019. „Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial.“ European Journal of Cancer, Nr. 120 doi: 10.1016/j.ejca.2019.07.026.
• Freundt, JK, Frommeyer, G, Spieker, T, Wötzel, F, Grotthoff, JS, Stypmann, J, Hempel, G, Schäfers, M, Jacobs, AH, Eckardt, L, und Lange, PS. 2019. „Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure.“ BMC pharmacology & toxicology, Nr. 2019 (20(1)) doi: 10.1186/s40360-019-0294-x.
• Pinder, N, Zimmermann, JB, Gastine, S, Würthwein, G, Hempel, G, Bruckner, T, Hoppe-Tichy, T, Weigand, MA, und Swoboda, S. 2019. „Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling.“ Biomedicine & Pharmacotherapy, Nr. 118 109318. doi: 10.1016/j.biopha.2019.109318.
• Kneller, LA, Abad-Santos, F, und Hempel, G. 2019. „Dose adjustment of risperidone in Cytochrome P450 2D6 intermediate- and poor metabolizer based on physiologically-based pharmacokinetic model.“ Beitrag präsentiert auf der Annual Meeting of the German Pharmaceutical Society – DPhG, Heidelberg, Germany
• Kneller, LA, Abad-Santos, F, und Hempel, G. 2019. „Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach.“ Beitrag präsentiert auf der Annual Meeting of the population approach group in Europe [PAGE], Stockholm, Sweden

2018

• Ellermann, I, Bueckmann, A, Eveslage, M, Buddendick, H, Latal, T, Niehoff, D, Geissler, RG, Hempel, G, Kerkhoff, A, Berdel, WE, Roeder, N, Van Aken, HK, Zarbock, A, und Steinbicker, AU. 2018. „Treating Anemia in the Preanaesthesia Assessment Clinic: Results of a Retrospective Evaluation.“ Anesthesia and Analgesia, Nr. 1 doi: 10.1213/ANE.0000000000003583.
• Völler, S, Pichlmeier, U, Zens, A, und Hempel, G. 2018. „Pharmacokinetics of recombinant asparaginase in children with achute lymphoblastic leukemia.“ Cancer Chemotherapy and Pharmacology, Nr. 81 (2): 305–314. doi: 10.1007/s00280-017-3492-5.
• Agyare, C, Spiegler, V, Asase, A, Scholz, M, Hempel, G, und Hensel, A. 2018. „An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana.“ Journal of Ethnopharmacology, Nr. 212: 137–152. doi: 10.1016/j.jep.2017.10.019.
• Perego, P, Hempel, G, Linder, S, Bradshaw, TD, Larsen, AK, Petres, GJ, und Philipps, RM. 2018. „Cellular pharmacology studies of anticancer agents:recommendations from the EORTIC-PAMM group.“ Cancer Chemotherapy and Pharmacology, Nr. 81 (3): 427–441. doi: 10.1007/s00280-017-3502-7.
• Völler, S, Pichlmeier, U, Zens, A, und Hempel, G. 2018. „Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.“ Cancer Chemotherapy and Pharmacology, Nr. 81 (2): 305–314. doi: 10.1007/s00280-17-3492-5.
• Dallmann, A, Ince, I, Coboeken, K, Eissing, T, und Hempel, G. 2018. „A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.“ Clinical Pharmacokinetics, Nr. 57 (6): 749–768. doi: 10.1007/s40262-017-0594-5.
• Gastine, S, Lehrnbecher, T, Müller, C, Farowski, F, Bader, P, Ullmann-Moskovits, J, Cornely, OA, Groll, AH, und Hempel, G. 2018. „Pharmacokinetic modeling of variconazole to develop an alternative dosing regimen in children.“ Antimicrobial Agents and Chemotherapy, Nr. 62
• Agyare, C, Spiegler, V, Asase, A, Scholz, M, Hempel, G, und Hensel, A. 2018. „An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana.“ Journal of Ethnopharmacology, Nr. 212: 137–152. doi: 10.1016/j.jep.2017.10.019.
• Lücht, UR, Weber, J, Rimmler, C, Scholz, WU, Brune, S, und Hempel, G. 2018. „Quantification of Pharmacokinetic Interactions: SCHOLZ Datenbank's MDDI-Calculator vs. Physiologically-Based Pharmacokinetic Modeling.“ Beitrag präsentiert auf der Annual Meeting of the German Pharmaceutical Society - DPhG, Hamburg, Germany
• Kneller, LA, Abad-Santos, F, und Hempel, G. 2018. „Physiologically-based Pharmacokinetic Modelling of Risperidone and its Active Metabolite 9-Hydroxyrisperidone in Subjects Genotypes for Cytochrome P450 2D6.“ Beitrag präsentiert auf der Annual Meeting of the German Pharmaceutical Society – DPhG, Hamburg, Germany

2017

• Völler, S, Hempel, G, Würthwein, G, Boddy, AV, Krischke, M, André, N, D'Incalci, M, Bisogno, G, und Boos, J. 2017. „Towards a Model-Based Dose Recommendation for Doxorubicin in Children.“ Clinical Pharmacokinetics, Nr. 56 (3): 215–223. doi: 10.1007/s40262-016-0451-y.
• A, Dallmann, I, Ince, Solodenko, M, Meyer, S, Willmann, T, Eissing, und G, Hempel. 2017. „Physiological based pharmacokinetic modeling of renally cleared drugs in pregnant women.“ Clinical Pharmacokinetics, Nr. 2017 doi: 10.1007/s40262-017-0538-0.
• Dallmann, A, Ince, I, Meyer, M, Willmann, S, Eissing, T, und Hempel, G. 2017. „Gestation-specific changes in the anatomy and physiology of healthy pregnant women:an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy.“ Clinical Pharmacokinetics, Nr. 2017 doi: 10.1007/s40262-017-0539-z.
• Radke, C, Horn, D, Lanckohr, C, Ellger, B, Meyer, M, Eissing, T, und Hempel, G. 2017. „Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.“ Clinical Pharmacokinetics, Nr. 56 doi: 10.1007/s40262-016-0475-3.
• Würthwein, G, Lanvers-Kaminsky, C, Hempel, G, Gastine, S, Möricke, A, Schrappe, M, Karlsson, M, und Boos, J. 2017. „Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia.“ European Journal of Drug Metabolism and Pharmacokinetics, Nr. 42 (6): 955–963. doi: 10.1007/s13318-017-0410-5.
• Gastine, S, Lehrnbecher, T, Müller, C, Farowski, F, Bader, P, Ullmann-Moskovits, J, Cornely, OA, Groll, AH, und Hempel, G. 2017. „Pharmakokinetic Modeling of Voriconazole to Develop an Alternative Dosing Regimen in Children.“ Antimicrobial Agents and Chemotherapy, Nr. 62 (1) doi: 10.1128/AAC.01194-17.
• Dickschen, KJ, Willmann, S, Hempel, G, und Block, M. 2017. „Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels.“ Frontiers in Pharmacology, Nr. 8 doi: 10.33380/fphar.2017.00067.
• Weber, J, Oberfeld, S, Bonse, A, Telger, K, Lingg, R, und Hempel, G. 2017. „Validation of a dried blood spot method for therapeutic drug monitoring of citalopram, mirtazapine and risperidone and its active metabolite 9-hydroxyrisperidone using HPLC–MS.“ Journal of Pharmaceutical and Biomedical Analysis, Nr. 2017 (140)
• Würthwein, G, Lanvers-Kaminsky, C, Hempel, G, Gastine, S, Möricke, A, Schrappe, M, Karlsson, MO, und Boos, J. 2017. „Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL.“ Beitrag präsentiert auf der PAGE 26, Budapest, Ungarn
• Wähnert, D, Roos, A, Glasbrenner, J, Ilting-Reuke, K, Ohrmann, P, Hempel, G, Duning, T, Roeder, N, und Raschke, MJ. 2017. „Alterstraumatologie Multimodale Delirprävention und Verwendung von Augmentationstechniken.“ Der Chirurg, Nr. 88
• Mahlknecht, A, Nestler, N, Bauer, U, Schüßler, N, Schuler, J, Scharer, S, Becker, R, Waltering, I, Hempel, G, Schwalbe, O, Flamm, M, und Osterbrink, J. 2017. „Effect of training and structured medication review on medication appropriateness in nursing home residents and on cooperation between health care professionals: the InTherAKT study protocol.“ BMC Geriatrics, Nr. 17 (1)
• Wähnert, D, Roos, A, Glasbrenner, J, Ilting-Reuke, K, Ohrmann, P, Hempel, G, Duning, T, Roeder, N, und Raschke, MJ. 2017. „Alterstraumatologie Multimodale Delirprävention und Verwendung von Augmentationstechniken.“ Der Chirurg, Nr. 88 (2): 95–104.
• Wähnert, Dirk, und Roos, AGlasbrenner J. Ilting-Reuke K. Ohrmann P. Hempel G. Duning T. Roeder N. Raschke M. 2017. „Alterstraumatologie: Multimodale Delirprävention und Verwendung von Augmentationstechniken.“ Der Chirurg, Nr. 88 (2): 95–104. doi: 10.1007/s00104-016-0339-2.

2016

• John, C, Herz, T, Boos, J, Langer, K, und Hempel, G. 2016. „Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.“ Talanta, Nr. 146: 335–339. doi: 10.1016/j.talanta.2015.08.028.
• Liebich, M, und Hempel, G. 2016. „Glucose as a cryoprotectant to stabilize liposomal daunorubicin (DaunoXome®) in frozen plasma for pharmacokinetic investigations.“ Beitrag präsentiert auf der EORTC-PAMM Winter, Antwerpen, Begium
• Radke, C, Horn, D, Lanckohr, C, Ellger, B, Meyer, M, Eissing, T, und Hempel, G. 2016. „Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis.“ Beitrag präsentiert auf der PAGE, Lissabon,Portugal
• Waltering, I, Schwalbe, O, und Hempel, G. 2016. „Information content of medication schedules prior to the implementation of the federal standard medication plan.“ Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, Nr. 115-1
• Krischke, M, Hempel, G, Völler, S, Andrè, N, D'Incalci, M, Bisogno, G, Köpcke, W, Borowski, M, Herold, R, Boddy, AV, und Boos, J. 2016. „Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" Trial.“ Cancer Chemotherapy and Pharmacology, Nr. 21
• Bartelink, IH, Lalmohamed, A, van Reij, EM, Dvorak, CC, Savic, RM, Zwaveling, J, Bredius, RG, Egberts, AC, Bierings, M, Kletzel, M, Shaw, PJ, Nath, CE, Hempel, G, Ansari, M, Krajinovic, M, Thèoret, Y, Duval, M, Keizer, RJ, Bittencourt, H, Hassan, M, Güngör, T, Wynn, RF, Veys, P, Cuvelier, GD, Marktel, S, Chiesa, R, Cowan, MJ, Slatter, MA, Stricherz, MK, Jennissen, C, Long-Boyle, JR, und Boelens, JJ. 2016. „Association of busulfan eyposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.“ The Lancet Haematology, Nr. 13
• Usman, M, und Hempel, G. 2016. „Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA).“ SpringerPlus, Nr. 5 doi: 10.1186/s40064-016-1778-4.
• John, C, Herz, T, Boos, J, Langer, K, und HempelG. 2016. „Asymmetrial flow field-flow fractionation for the analysis of PEG-asparaginase.“ Talanta, Nr. 146: 335–339.
• Lanckohr, C, Horn, D, Voeller, S, Hempel, G, Fobker, M, Welp, H, Koeck, R, und Ellger, B. 2016. „Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery.“ Journal of Thoracic and Cardiovascular Surgery, Nr. 152 (2): 603–610. doi: 10.1016/j.jtcvs.2016.04.024.
• Krischke, M, Hempel, G, Völler, S, André, N, D’Incalci, M, Bisogno, G, Köpcke, W, Borowski, M, Herold, R, Boddy, AV, und Boos, J. 2016. „Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial.“ Cancer Chemotherapy and Pharmacology, Nr. 78 (6): 1175–1184. doi: 10.1007/s00280-016-3174-8.

2015

• John, C., Herz, T., Boos, J., Langer, K., und Hempel, G. 2015. „A novel asymmetrical flow field-flow fractionation for the analysis of PEG asparaginase.“ Talanta, Nr. 146: 335–339.
• Horn, D, und Hempel, G. 2015. „Spesis.“ In Angewandte Pharmakotherapie, herausgegeben von O Rose und K Friedland. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
• Hempel, G, und Ritter, J. 2015. „Leukämie.“ In Angewandte Pharmakotherapie, herausgegeben von O Rose und K Friedland. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
• Waltering, I, Schwalbe, O, und Hempel, G. 2015. „Discrepancies on Medication Plans detected in German Community Pharmacies.“ Journal of Evaluation in Clinical Practice, Nr. 21 (21(5)): 886–892.
• Völler, S, Boos, J.Krischke M, Würthwein, G, Kontny, NE, Boddy, AV, und Hempel, G. 2015. „Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.“ Clinical Pharmacokinetics, Nr. 54: 1139–1149. doi: 10.1007/s40262-015-0272-4.
• Stader, F, Wuerthwein, G, Groll, AH, Vehreschild, JJ, Cornely, OA, und Hempel, G. 2015. „Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.“ Pharmaceutical Research, Nr. 32: 2029–2037.
• Drogouti, E., Pana, Z., Tragiannidis, A., Hempel, G., und Groll, A. 2015. „Clinical pharmacology of itraconazole in children and adolescents.“ Current Fungal Infection Reports, Nr. 9 (2): 65–73. doi: 10.1007/s12281-015-0218-1.
• Henrichsmann, M, und Hempel, G. 2015. „Impact of medication therapy management in patients with Parkinson's disease.“ International Journal of Clinical Pharmacy, Nr. 38 (1): 54–60. doi: 10.1007/s11096-015-0206-0.
• Goedecke, S, Mühlisch, J, Hempel, G, Frühwald, MC, und Wünsch, B. 2015. „Quantitative analysis of DNA methylation in the promoter region of the methylguanine-O6-DNA-methyltransferase gene by COBRA and subsequent native capillary gel electrophoresis.“ Electrophoresis, Nr. 2015 doi: 10.1002/elps.201500242.

2014

• Hempel, G. 2014. „Physiology-Based Pharmacokinetic Modeling - Promise for Paediatric Drug Development?“ Current Fungal Infection Reports, Nr. 8: 67–71.
• Geier, AS, Wellmann, I, Wellmann, J, Kajüter, H, Heidinger, O, Hempel, G, und Hense, HW. 2014. „Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.“ Diabetes Research and Clinical Practice, Nr. 106: 73–80.
• Diestelhorst, C, Boos, J, McCune, JS, Russell, J, Kangarloo, SB, und Hempel, G. 2014. „Predictive Performance of a Physilogocally Based Pharmacokinetic Model of Busulfan in Children.“ Pediatric Hematology-Oncology, Nr. 2014 (31(8)): 731–742. doi: 10.3109/08880018.2014.927945.
• Dickschen, K, Eissing, T, Mürdter, T, Schwab, M, Willmann, S, und Hempel, G. 2014. „Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.“ SpringerPlus, Nr. 5 (3): 285.
• Borghorst, S, Hempel, G, Poppenborg, S, Franke, D, König, T, und Baumgart, J. 2014. „Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dog.“ Cancer Chemotherapy and Pharmacology, Nr. 74: 367–378.
• Diestelhorst, C, Boos, J, McCune, JS, und Hempel, G. 2014. „Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM model to optimize dosing.“ European Journal of Clinical Pharmacology, Nr. 70 (7): 839–847. doi: 10.1007/s00228-014-1692-z.
• Kerl, K, Diestelhorst, C, Bartelink, I, Boelens, J, Trame, MN, Boos, J, und Hempel, G. 2014. „Evaluation of effects of busulfan and DMA on SOS in pedriatic stem cell recipients.“ Pediatric Blood and Cancer, Nr. 61: 306–311. doi: 10.1002/pbc.24827.
• Kerl, K, Diestelhorst, C, Bartelink, I, Boelens, J, Trame, MN, Boos, J, und Hempel, G. 2014. „Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients.“ Pediatric blood & cancer, Nr. 61 (2): 306–311. doi: 10.1002/pbc.24827.
• Bernemann, C, Hülswig, C, Ruckert, C, Schäfer, S, Blümel, L, Hempel, G, Götte, M, Greve, B, Barth, PJ, Kiesel, L, und Liedtke, C. 2014. „Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.“ Molecular Cancer, Nr. 2014 (13): 174. doi: 10.1186/1476-4598-13-174.

2013

• Würthwein, G, Cornely, OA, Trame, M, Vehreschild, JJ, Vehreschild, MJ, Farowski, F, Müller, C, Boos, J, Hempel, G, Hallek, M, und Groll, AH. 2013. „Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.“ Antimicrobial Agents and Chemotherapy, Nr. 57 (4): 1664–1671.
• Trame, MN, Bartelink, IH, Boos, J, Boelens, JJ, und Hempel, G. 2013. „Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.“ Cancer Chemotherapy and Pharmacology, Nr. 72 (5): 1149–1155. doi: 10.1007/s00280-013-2284-9.
• Diestelhorst, C, Boos, J, McCune, JS, Russell, J, Kangarloo, SB, und Hempel, G. 2013. „Physiologically based pharmacokinetic modelling of Busulfan: A new approach to describe and predict the pharmacokinetics in adults.“ Cancer Chemotherapy and Pharmacology, Nr. 72 (5): 991–1000. doi: 10.1007/s00280-013-2275-x.
• Geier, A.S., Wellmann, J., Wellmann, I., Kajuter, H., Heidinger, O., Hempel, G., und Hense, H.W. 2013. „Cancer detection rates following enrolment in a disease management programme for type 2 diabetes.“ Diabetologia, Nr. 56 (9): 1944–1948. doi: 10.1007/s00125-013-2947-4.
• Kontny, NE, Würthwein, G, Boos, J, Boddy, AV, Krischke, M, Fuhr, U, Thompson, PA, Jörger, M, Schellens, JH, und Hempel, G. 2013. „Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.“ Cancer Chemotherapy and Pharmacology, Nr. 71 (3): 749–763. doi: 10.1007/s00280-013-2069-1.
• Henschel, AD, Rothenberger, LG, Schrey, D, Gerß, J, Hempel, G, und Boos, J. 2013. „Risk and benefit from clinical trials in minors: Making the case for transparent and consistent publications.“ Open Journal of Pediatrics, Nr. 03 (02): 151–164. doi: 10.4236/ojped.2013.32027.

2012

• Storzinger, D., Borghorst, S., Hofer, S., Busch, C.J., Lichtenstern, C., Hempel, G., Weigand, M.A., und Hoppe-Tichy, T. 2012. „Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.“ Antimicrobial Agents and Chemotherapy, Nr. 56 (8): 4468–4470. doi: 10.1128/AAC.06167-11.
• Dickschen, K., Willmann, S., Thelen, K., Lippert, J., Hempel, G., und Eissing, T. 2012. „Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance.“ Frontiers in Pharmacology, Nr. null (null) doi: 10.3389/fphar.2012.00092.
• Falck, E., Groenhagen, A., Muhlisch, J., Hempel, G., und Wunsch, B. 2012. „Genome-wide DNA methylation level analysis by micellar electrokinetic chromatography and laser-induced fluorescence detection after treatment of cell lines with azacytidine and antifolates.“ Analytical Biochemistry, Nr. 421 (2): 439–445. doi: 10.1016/j.ab.2011.09.027.
• Fischer, U., Schuler, K., Siebert, S., Smollich, M., Elkeles, B., Hempel, G., und Kruse, J. 2012. „Formulation - Quality in seven steps. Step 1: Comply with hygiene standards.“ Deutsche Apotheker-Zeitung, Nr. 152 (37): 62–73.
• Bartelink, I.H., Boelens, J.J., Bredius, R.G.M., Egberts, A.C.G., Wang, C., Bierings, M.B., Shaw, P.J., Nath, C.E., Hempel, G., Zwaveling, J., Danhof, M., und Knibbe, C.A.J. 2012. „Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: Towards individualized dosing.“ Clinical Pharmacokinetics, Nr. 51 (5): 331–345. doi: 10.2165/11598180-000000000-00000.
• Trame, MN, Bergstrand, M, Karlsson, MO, und Hempel, G. 2012. „Population Pharmacokinetics of Busulfan in Children-Response.“ Clinical Cancer Research, Nr. 18 (9): 2717–2718. doi: 10.1158/1078-0432.CCR-12-0425.
• Kontny, NE, Boos, J, Würthwein, G, Hempel, G, Boddy, AV, Groll, AH, und Krischke, M. 2012. „Minization of the preanalytical error in pharmacokinetic analyses and therapeutic drug monitoring: focus on IV drug administration.“ Therapeutic Drug Monitoring, Nr. 34 (4): 460–466. doi: 10.1097/FTD.0b013e31825a4d9c.
• Borghorst, S, Pieters, R, Kuehnel, HJ, Boos, J, und Hempel, G. 2012. „Population pharmacokinetics of native Escheria coli asparaginase.“ Clinical Trials, Nr. 29 (2): 154–165. doi: 10.3109/08880018.2011.627978.
• Siebert, S, Elkeles, B, Hempel, G, Kruse, J, und Smollich, M. 2012. „Die PRISCUS-Liste im klinischen Test; Praktikabilität und Vergleich mit internationalen PIM-Listen.“ Zeitschrift für Gerontologie und Geriatrie, Nr. 46: 35–47.
• Reimer, J, Bien, S, Ameling, S, Hammer, E, Völker, U, Hempel, G, Boss, J, Kroemer, HK, und Ritter, CA. 2012. „Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.“ European Journal of Clinical Pharmacology, Nr. 68 (6): 923–935. doi: 10.1007/s00228-011-1209-y.
• Kersting, G, Willmann, S, Würthwein, G, Lippert, J, Boos, J, und Hempel, G. 2012. „Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.“ Cancer Chemotherapy and Pharmacology, Nr. 69 (2): 397–405. doi: 10.1007/s00280-011-1706-9.
• Würthwein, G, Young, C, Lanvers-Kaminsky, C, Hempel, G, Trame, M, Schwerdtfeger, R, Ostermann, H, Heinz, W, Cornely, O, Kolve, H, Boos, J, Silling, G, und Groll, A. 2012. „Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.“ Antimicrobial Agents and Chemotherapy, Nr. 56 (1): 536–543. doi: 10.1128/AAC.00265-11.

2011

• Kontny, NE, Hempel, G, Boos, J, Boddy, AV, und Krischke, M. 2011. „Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring-using doxorubicin as an example.“ Therapeutic Drug Monitoring, Nr. 33 (6): 766–771. doi: 10.1097/FTD.0b013e31823aa8ab.
• Hempel, G., und Trame, M.N. 2011. „Therapeutic drug monitoring of busulfan.“ Clinical Chemistry, Nr. 57 (4): 643–644. doi: 10.1373/clinchem.2010.155374.
• Trame, MN, Bergstrand, M, Karlsson, MO, Boos, J, und Hempel, G. 2011. „Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.“ Clinical Cancer Research, Nr. 17 (21): 6867–6877. doi: 10.1158/1078-0432.CCR-11-0074.
• Hempel, G, und Baum, S, Hrsg. 2011. Geriatrische Pharmazie. Eschborn: Govi.
• Horn, DG, Trame, MN, und Hempel, G. 2011. „The management of hypertensive emergencies in children after stem cell transplantation.“ International Journal of Clinical Pharmacy, Nr. 33: 165–176.

2010

• Swoboda, S, Ober, MC, Lichtenstern, C, Saleh, S, Schwenger, V, Sonntag, H-G, Haefeli, WE, Hempel, G, Hoppe-Tichy, T, und Weigand, MA. 2010. „Pharmacokinetics of linezolid in septic patients with and without extended dialysis.“ European Journal of Clinical Pharmacology, Nr. 66 (3): 291–298. doi: 10.1007/s00228-009-0766-9.
• Trame, MN, Mitchell, L, Krümpel, A, Male, C, Hempel, G, und Nowak-Göttl, U. 2010. „Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: A cohort study.“ Journal of Thrombosis and Haemostasis, Nr. 8 (9): 1950–1958. doi: 10.1111/j.1538-7836.2010.03964.x.
• Hempel, G, Müller, HJ, Lanvers-Kaminsky, C, Würthwein, G, Hoppe, A, und Boos, J. 2010. „A population pharmacokinetic model for pegylated-asparaginase in children.“ British Journal of Haematology, Nr. 148 (1): 119–125. doi: 10.1111/j.1365-2141.2009.07923.x.
• Hempel, G, Relling, MV, de Rossi, G, Stary, J, De Lorenzo, P, Valsecchi, MG, Barisone, E, Boos, J, und Pieters, R. 2010. „Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.“ Pediatric Blood and Cancer, Nr. 54 (3): 355–360. doi: 10.1002/pbc.22266.
• Schrey, D, Borghorst, S, Lanvers-Kaminsky, C, Hempel, G, Gerss, J, Möricke, A, Schrappe, M, und Boos, J. 2010. „Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.“ Pediatric Blood and Cancer, Nr. 54 (7): 952–958. doi: 10.1002/pbc.22417.
• Niemann, A, Mühlisch, J, Frühwald, MC, Gerss, J, Hempel, G, und Boos, J. 2010. „Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?“ Therapeutic Drug Monitoring, Nr. 32 (4): 467–475. doi: 10.1097/FTD.0b013e3181e5c6b3.

2009

• Schrauder, A, Saleh, S, Sykora, KW, Hoy, H, Welte, K, Boos, J, Hempel, G, und Grigull, L. 2009. „Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.“ Pediatric Transplantation, Nr. 13 (4): 444–450. doi: 10.1111/j.1399-3046.2008.00968.x.
• Goedecke, S, Schlosser, S, Mühlisch, J, Hempel, G, Frühwald, MC, und Wünsch, B. 2009. „Accurate quantification of DNA methylation of DRD4 applying capillary gel electrophoresis with LIF detection.“ Electrophoresis, Nr. 30 (8): 1412–1417. doi: 10.1002/elps.200800567.
• Groll, AH, Young, C, Lanvers-Kaminsky, C, Silling, G, Hempel, G, Boos, J, und Wurthwein, G. 2009. „Population pharmacokinetics of liposomal amphotericin B, caspofungin and the combination of both in allogeneic hematopoietic stem cell recipients.“ Beitrag präsentiert auf der 4th Trends in Medical Mycology, Athen, Deutschland doi: 10.1111/j.1439-0507.2009.01782.x.
• Goedecke, S, Schlosser, S, Muhlisch, J, Hempel, G, Fruhwald, MC, und Wünsch, B. 2009. „Determination of DNA methylation by COBRA: A comparative study of CGE with LIF detection and conventional gel electrophoresis.“ Electrophoresis, Nr. 30 (17): 3063–3070. doi: 10.1002/elps.200900204.

2008

• Koling, S, und Hempel, G. 2008. „Arzneimitteltherapie im Kindesalter: Die sichere und effektive Dosis finden.“ Pz Prisma, Nr. 15 (2): 68–78.
• Groenhagen, A, Kallinger, B, Hempel, G, Lanvers-Kaminsky, C, Muhlisch, J, Boos, J, Jurgens, H, und Fruhwald, MC. 2008. „The impact of antifolate therapy on the genome and epigenome.“ Klinische Pädiatrie, Nr. 220 (3): 201–201.
• Niemann, A, Boos, J, Muhlisch, J, Fruhwald, MC, und Hempel, G. 2008. „Determination of methotrexate and its main metabolite in cerebrospinal fluid after High-Dose Methotrexate by LC-MS.“ Klinische Pädiatrie, Nr. 220 (3): 205–205.
• Hempel, G. 2008. „Kommentar zur Monographie Paclitaxel des Europäischen Arzneibuchs.“ In Kommentar zum Ph. Eur. Ausgabe 5.8, herausgegeben von G Scriba. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

2007

• Hempel, G, und Boos, J. 2007. „Comment on "Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation" by F.K. Glowka et al. [J. Chromatogr. B 850 (2007) 569-574].“ Journal of Chromatography B, Nr. 853 (1-2): 369–370.
• Hempel, G, Oechtering, D, Lanvers-Kaminsky, C, Klingebiel, T, Vormoor, J, Gruhn, B, und Boos, J. 2007. „Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.“ Journal of Clinical Oncology, Nr. 25 (13): 1772–1778. doi: 10.1200/JCO.2006.08.8807.
• Hempel, G, und Boos, J. 2007. „Flat-fixed dosing versus body surface area-based dosing of anticancer drugs: There is a difference.“ Oncologist, Nr. 12 (8): 924–926. doi: 10.1634/theoncologist.12-8-924.
• Koling, S, Hempel, G, Lanvers, C, Boos, J, und Würthwein, G. 2007. „Monitoring paracetamol metabolism after single and repeated administration in pediatric patients with neoplastic diseases.“ International Journal of Clinical Pharmacology and Therapeutics, Nr. 45 (9): 496–503. doi: 10.5414/cpp45496.
• Hunz, M, Jetter, A, Warm, M, Pantke, E, Tuscher, M, Hempel, G, Jaehde, U, Untch, M, Kurbacher, C, und Fuhr, U. 2007. „Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.“ Clinical Pharmacology and Therapeutics, Nr. 81 (5): 659–668. doi: 10.1038/sj.clpt.6100067.
• Joerger, M, Huitema, ADR, Richel, DJ, Dittrich, C, Pavlidis, N, Briasoulis, E, Vermorken, JB, Strocchi, E, Martoni, A, Sorio, R, Sleeboom, HP, Izquierdo, MA, Jodrell, DI, Féty, R, De Bruijn, E, Hempel, G, Karlsson, M, Tranchand, B, Schrijvers, AHGJ, Twelves, C, Beijnen, JH, und Schellens, JHM. 2007. „Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG.“ Clinical Pharmacokinetics, Nr. 46 (12): 1051–1068. doi: 10.2165/00003088-200746120-00005.
• Wilde, S, Jetter, A, Rietbrock, S, Kasel, D, Engert, A, Josting, A, Klimm, B, Hempel, G, Reif, S, Jaehde, U, Merkel, U, Busse, D, Schwab, M, Diehl, V, und Fuhr, U. 2007. „Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.“ Clinical Pharmacokinetics, Nr. 46 (4): 319–333. doi: 10.2165/00003088-200746040-00005.
• Hempel, G. 2007. „Populationspharmakokinetik.“ In Repetitorium Klinische Pharmazie, herausgegeben von P Högger und E Strehl. Eschborn: Govi.
• Hempel, G. 2007. „Pharmakogenetik.“ In Repetitorium Klinische Pharmazie, herausgegeben von P Högger und E Strehl. Eschborn: Govi.
• Hempel, G, und Boos, J. 2007. „Comment on "Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation" by F.K. Glowka et al. J. Chromatogr. B 850 (2007) 569-574.“ Journal of Chromatography B, Nr. 853 (1-2): 369–370. doi: 10.1016/j.jchromb.2007.02.060.
• Hempel, G, und Boos, J. 2007. „Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.“ Oncologist, Nr. 12 (8): 924–926. doi: 10.1634/theoncologist.12-8-924.
• Armstrong, JK, Hempel, G, Koling, S, Chan, LS, Fisher, T, Meiselman, HJ, und Garratty, G. 2007. „Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.“ Cancer, Nr. 110 (1): 103–111. doi: 10.1002/cncr.22739.
• Joerger, M, Huitema, ADR, Richel, DJ, Dittrich, C, Pavlidis, N, Briasoulis, E, Vermorken, JB, Strocchi, E, Martoni, A, Sorio, R, Sleeboom, HP, Izquierdo, MA, Jodrell, DI, Calvert, AH, Boddy, A, Hollema, H, Fety, R, Van der, Vijgh W JF, Hempel, G, Chatelut, E, Karlsson, M, Tranchand, B, Schrijvers, AHGJ, Beijnen, JH, und Schellens, JHM. 2007. „Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG.“ British Journal of Clinical Pharmacology, Nr. 63 (4): 505–505. doi: 10.1111/j.1365-2125.2007.02886_4.x.

2006

• Ünsalan, S, Hempel, G, Fobker, M, Würthwein, G, und Boos, J. 2006. „Monitoring of mycophenolic acid in the plasma of transplant patients by capillary electrophoresis.“ Chromatographia, Nr. 64 (7-8): 419–421. doi: 10.1365/s10337-006-0046-0.
• Oechtering, D, Boos, J, und Hempel, G. 2006. „Monitoring of N,N-dimethylacetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry.“ Journal of Chromatography B, Nr. 838 (2): 129–134. doi: 10.1016/j.jchromb.2006.04.034.
• Saleh, S, und Hempel, G. 2006. „Quantification of ganciclovir in human plasma using capillary electrophoresis.“ Electrophoresis, Nr. 27 (12): 2439–2443. doi: 10.1002/elps.200500903.
• Lanvers-Kaminsky, C, und Hempel, G. 2006. „Preclinical and Clinical Aspects of Asparaginase.“ European Journal of Hospital Pharmacy: Science and Practice, Nr. 12 (5): 45–46.
• Hempel, G. 2006. „Kommentar zur Monographie Buspironhydrochlorid des Europäischen Arzneibuchs.“ In Kommentar zum Ph. Eur. Ausgabe 5.4, herausgegeben von G Scriba. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
• Hempel, G. 2006. „Kommentar zur Monographie Emedastindifumarat des Europäischen Arzneibuchs.“ In Kommentar zum Ph. Eur. Ausgabe 5.4, herausgegeben von G Scriba. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

2005

• Lingg, RM, Hempel, G, Rots, MG, Van Zantwijk, CH, Boos, J, und Kaspers, GJL. 2005. „Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay.“ Cancer Chemotherapy and Pharmacology, Nr. 56 (3): 322–327. doi: 10.1007/s00280-005-1032-1.
• Hempel, G, Lingg, R, und Boos, J. 2005. „Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: Implications for the application in case of methotrexate intoxications.“ Cancer Chemotherapy and Pharmacology, Nr. 55 (4): 347–353. doi: 10.1007/s00280-004-0910-2.
• Oechtering, D, Schiltmeyer, B, Hempel, G, Schwab, M, Würthwein, G, Mürdter, T, Klingebiel, T, Vormoor, J, Gruhn, B, Fleischack, G, und Boos, J. 2005. „Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation.“ Anti-Cancer Drugs, Nr. 16 (3): 337–344. doi: 10.1097/00001813-200503000-00014.
• Würthwein, G, Koling, S, Reich, A, Hempel, G, Schulze-Westhoff, P, Pinheiro, PV, und Boos, J. 2005. „Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery.“ European Journal of Clinical Pharmacology, Nr. 60 (12): 883–888. doi: 10.1007/s00228-004-0873-6.
• Würthwein, G, Groll, AH, Hempel, G, Adler-Shohet, FC, Lieberman, JM, und Walsh, TJ. 2005. „Population pharmacokinetics of amphotericin B lipid complex in neonates.“ Antimicrobial Agents and Chemotherapy, Nr. 49 (12): 5092–5098. doi: 10.1128/AAC.49.12.5092-5098.2005.
• Würthwein, G, Koling, S, Reich, A, Hempel, G, Schulze-Westhoff, P, Pinheiro, PV, und Boos, J. 2005. „Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery.“ European Journal of Clinical Pharmacology, Nr. 60 (12): 883–888. doi: 10.1007/s00228-004-0873-6.

2004

• Hempel, G. 2004. „Dose and therapy individualisation in cancer chemotherapy.“ In Drug Monitoring and Clinical Chemistry, Handbook of Analytical Seperations Vol 5, herausgegeben von G Hempel. Amsterdam: Elsevier. doi: 10.1016/S1567-7192(04)80008-1.

2003

• Flege, S, Griese, N, und Hempel, G. 2003. „Drug Monitoring von Anthrazyklinen: Teil 1: Chemie, Wirkung, Nebenwirkung und Pharmakokinetik.“ Pz Prisma, Nr. 10 (1): 29–36.
• Flege, S, Griese, N, und Hempel, G. 2003. „Drug Monitoring von Anthrazyklinen Teil 2: Monitoring bei Kindern, Reduktion der Kardiotoxizität, Fallbeispiele.“ Pz Prisma, Nr. 10 (2): 105–117.
• Hempel, G, Reinhardt, D, Creutzig, U, und Boos, J. 2003. „Population pharmacokinetics of liposomal daunorubicin in children.“ British Journal of Clinical Pharmacology, Nr. 56 (4): 370–377. doi: 10.1046/j.1365-2125.2003.01886.x.
• Hempel, G, Rübe, C, Mosler, C, Wienstroer, M, Wagner-Bohn, A, Schuck, A, Willich, N, und Boos, J. 2003. „Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors.“ Anti-Cancer Drugs, Nr. 14 (6): 417–422. doi: 10.1097/00001813-200307000-00005.
• Schiltmeyer, B, Klingebiel, T, Schwab, M, Mürdter, TE, Ritter, CA, Jenke, A, Ehninger, G, Gruhn, B, Würthwein, G, Boos, J, und Hempel, G. 2003. „Population pharmacokinetics of oral busulfan in children.“ Cancer Chemotherapy and Pharmacology, Nr. 52 (3): 209–216. doi: 10.1007/s00280-003-0631-y.
• Hempel, G. 2003. „Biomedical applications of capillary electrophoresis.“ Clinical Chemistry and Laboratory Medicine, Nr. 41 (6): 720–723. doi: 10.1515/CCLM.2003.111.

2002

• Griese, N, Blaschke, G, Boos, J, und Hempel, G. 2002. „Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis.“ Journal of Chromatography A, Nr. 979 (1-2): 379–388. doi: 10.1016/S0021-9673(02)01440-1.
• Lingg, RM, Rots, MG, Van Zantwijk, CH, Hempel, G, Kaspers, GJL, und Boos, J. 2002. „Effect and interaction of 7-hydroxy methotrexate and methotrexate in AML and ALL patients samples: Measured by the thymidylate synthase inhibition assay.“ International Journal of Clinical Pharmacology and Therapeutics, Nr. 40 (8): 382–384.
• Hempel, G, Flege, S, Würthwein, G, und Boos, J. 2002. „Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.“ Cancer Chemotherapy and Pharmacology, Nr. 49 (2): 133–141. doi: 10.1007/s00280-001-0392-4.
• Busse, D, Würthwein, G, Hinske, C, Hempel, G, Fromm, MF, Eichelbaum, M, Kroemer, HK, und Busch, FW. 2002. „Pharmacokinetics of intravenous etoposide in patients with breast cancer: Influence of dose escalation and cyclophosphamide and doxorubicin coadministration.“ Naunyn-Schmiedeberg's Archives of Pharmacology, Nr. 366 (3): 218–225. doi: 10.1007/s00210-002-0594-2.
• Schiltmeyer, B, Hempel, G, Schwab, M, Ritter, C, Klingebiel, T, und Boos, J. 2002. „Population pharmacokinetics of oral busulfan in children.“ International Journal of Clinical Pharmacology and Therapeutics, Nr. 40 (8): 385–386.
• Reinhardt, D, Hempel, G, Fleischhack, G, Schulz, A, Boos, J, und Creutzig, U. 2002. „Effektive Rezidivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem Daunorubicin und Cytarabin.“ Klinische Pädiatrie, Nr. 214 (4): 188–194. doi: 10.1055/s-2002-33185.
• Wilde, S, Jetter, A, Zaigier, M, Rietbrock, S, Menzel, H, Sieber, M, Tesch, H, Hempel, G, Busse, D, Schwab, M, Reif, S, Jaehde, U, Diehl, V, und Fuhr, U. 2002. „Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy.“ International Journal of Clinical Pharmacology and Therapeutics, Nr. 40 (12): 586–588.
• Lanvers, C, Pinheiro, JPV, Hempel, G, Wuerthwein, G, und Boos, J. 2002. „Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.“ Analytical Biochemistry, Nr. 309 (1): 117–126. doi: 10.1016/S0003-2697(02)00232-4.

2001

• Ünsalan, S, Hempel, G, Boos, J, und Blaschke, G. 2001. „Determination of mycophenolic acid and its glucuronide conjugate in human plasma by capillary electrophoresis.“ Chromatographia, Nr. 54 (9-10): 635–637. doi: 10.1007/BF02492191.
• Laubrock, N, Schulze-Westhoff, P, Würthwein, G, Flege, S, Lanvers, C, und Hempel, G. 2001. „Drug-monitoring von Anthracyclinen - Untersuchungen zur Minimierung präanalytischer Fehler bei der Gewinnung von Plasmaproben.“ Krankenhauspharmazie KPH, Nr. 22 (4): 166–169.
• Wessel, T, Breitkreutz, J, Ahlke, E, Hempel, G, und Boos, J. 2001. „Probleme bei der Dauertherapie mit Mercaptopurin-Tabletten.“ Krankenhauspharmazie KPH, Nr. 22 (7): 325–329.
• Hempel, G, Schulze-Westhoff, P, Flege, S, und Boos, J. 2001. „Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis.“ Journal of chromatography B: Biomedical sciences and applications, Nr. 758 (2): 221–228. doi: 10.1016/S0378-4347(01)00185-2.
• Soetebeer, UB, Schierenberg, M-O, Schulz, H, Hempel, G, Andresen, P, und Blaschke, G. 2001. „Simultaneous quantification of etoposide and etoposide phosphate in human plasma by capillary electrophoresis using laser-induced native fluorescence detection.“ Analytical Chemistry, Nr. 73 (10): 2178–2182. doi: 10.1021/ac001467v.
• Torsten, Wessel, Jörg, Breitkreutz, Elvira, Ahlke, Georg, Hempel, und Joachim, Boos. 2001. „Probleme bei der Dauertherapie mit Mercaptopurin-Tabletten.“ Krankenhauspharmazie, Nr. 22 (7): 325–329.
• Flege, S, Hempel, G, Schulze-Westhoff, P, Laubrock, N, und Boos, J. 2001. „Drug Monitoring of Doxorubicin in Children.“ In Acute Leukemias VIII, Bd. 40 aus Haematology and Blood Transfusion, herausgegeben von T Büchner, W Hiddemann, B Wörmann, G Schellong, J Ritter und U Creutzig. Düsseldorf: Springer VDI Verlag.
• Wessel, T, Hempel, G, und Boos, J. 2001. „Drug Monitoring during Maintenance Therapy in Children with ALL.“ In Acute Leukemias VIII, Bd. 40 aus Haematology and Blood Transfusion, herausgegeben von T Büchner, W Hiddemann, B Wörmann, G Schellong, J Ritter und U Creutzig. Düsseldorf: Springer VDI Verlag. doi: 10.1007/978-3-642-18156-6_40.